A fluorescent compound, PD-L1 targeting probe and application thereof

By developing the fluorescent compound BMS-1166 and its targeted probe, the problem of monitoring the spatiotemporal heterogeneity of PD-L1 molecules in the tumor immune microenvironment is solved, and accurate imaging detection of tumors is realized, providing effective means for early detection of tumors. , has the characteristics of high signal-to-noise ratio and safety and reliability.

CN118754891BActive Publication Date: 2024-12-06INST OF AUTOMATION CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411253984.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-06
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

The prior art is difficult to effectively monitor and evaluate the spatiotemporal heterogeneity of PD-L1 molecules in the tumor immune microenvironment, which affects the insufficient response rate of immune checkpoint inhibitor treatment, and traditional tumor tissue puncture sampling is difficult to reflect the spatiotemporal globality of the sample.

Method used

Develop a fluorescent compound BMS-1166 and its targeted probe to achieve accurate imaging detection of tumors by binding specifically to PD-L1, and use fluorescent compounds BMS-1166-5-FAM and BMS-1166-Cy5.5 to perform. Targeting evaluation, dynamic non-invasive evaluation in cells and animals in combination with fluorescent dyes with high targeting.

Benefits of technology

Accurate imaging detection of tumor PD-L1 expression is realized, which can dynamically evaluate PD-L1 expression in tumor tissues, has a high signal-to-noise ratio, and is suitable for early detection of tumors such as breast cancer, colon cancer and melanoma. And it has no toxic side effects and is simple in process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118754891B_ABST
    Figure CN118754891B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and specifically relates to a fluorescent compound, a PD-L1 targeted probe and its application. The fluorescent compound of the present invention is obtained by coupling BMS-1166 with a fluorescent dye. The fluorescent compound can be used for accurate imaging of tumors to detect PD-L1 expression and can specifically image tumor tissues, and can be used for early detection of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a fluorescent compound, a PD-L1 targeting probe and applications thereof. Background Art

[0002] In recent years, immunotherapy has become the fourth cancer treatment method after surgery, radiotherapy, and chemotherapy, bringing new hope to patients and significantly improving the survival rate of cancer patients. However, due to the strong spatiotemporal heterogeneity of tumor immune microenvironment (TIME) molecular expression, the response rate of immune checkpoint inhibitors is less than 30%. Therefore, dynamic monitoring of programmed death 1 ligand 1 (PD-L1) molecular expression in TIME is helpful to comprehensively evaluate the expression of PD-L1, which is of great significance for the accurate detection of tumors and the development of new strategies for combined immunotherapy. However, the current research on TIME molecular expression mainly relies on immunohistochemical analysis of tumor tissue after puncture or surgery. This local puncture sampling is difficult to reflect the global view of the sample in time and space. As a non-invasive and sensitive in vivo detection method, molecular imaging provides the possibility of dynamic global visualization of TIME, analysis of its internal regulatory mechanism, and assistance in individualized immunotherapy decision-making.

[0003] In many tumors, PD-L1 downregulates the body's cellular immune response, allowing tumor cells to escape the immune system's attack. Normally, PD-L1 is highly expressed in tumor tissues relative to normal tissues. Therefore, the field expects to develop a reagent that can be used for accurate imaging of tumors to detect PD-L1 expression, which has positive significance for tumor detection. Summary of the invention

[0004] To this end, the first object of the present invention is to provide a fluorescent compound, in particular a BMS-1166 fluorescent compound, which can be used to detect the expression of PD-L1 and thus achieve accurate imaging of tumors;

[0005] The second object of the present invention is to provide a PD-L1 targeting probe that can be used to detect the expression of PD-L1;

[0006] The third object of the present invention is to provide the use of the above-mentioned fluorescent compound and PD-L1 targeting probe for preparing tumor detection reagents.

[0007] In order to solve the above technical problems, the present invention provides a fluorescent compound having a structure shown in the following formula (I):

[0008] ;

[0009] (I)

[0010] Wherein, the Y includes a fluorescent group.

[0011] Specifically, the fluorescent compound includes a compound BMS-1166-5-FAM having a structure shown in the following formula (a):

[0012] .

[0013] Specifically, the fluorescent compound includes a compound BMS-1166-Cy5.5 having a structure shown in the following formula (a):

[0014] .

[0015] The present invention also discloses a method for preparing the fluorescent compound, comprising the following steps:

[0016] (1) In an organic solvent system, compound BMS-1166 and a fluorescent raw material of a selected structure are taken, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 4-dimethylaminopyridine are added to react;

[0017] (2) Collect the reactants and purify them on a silica gel column to obtain the product.

[0018] Specifically, in the method for preparing the fluorescent compound, in the step (1), the fluorescent raw material includes 5-carboxyfluorescein and / or Cy5.5-COOH;

[0019] The mass ratio of the compound BMS-1166, the fluorescent raw material, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 4-dimethylaminopyridine is 1:1:5:0.1.

[0020] Preferably, the organic solvent comprises N , N -Dimethylformamide.

[0021] Specifically, in the method for preparing the fluorescent compound, in step (2), the silica gel column purification step includes the step of eluting with a mixed solvent of methanol and dichloromethane, and the step of removing the solvent under reduced pressure.

[0022] Preferably, the volume ratio of methanol to dichloromethane is 8-12:1, more preferably 10:1.

[0023] The present invention also discloses a PD-L1 targeting probe, comprising the fluorescent compound.

[0024] The present invention also discloses a tumor detection preparation, comprising the fluorescent compound or the PD-L1 targeting probe.

[0025] The present invention also discloses the use of the fluorescent compound for preparing a product having at least one of the following effects (1) to (3):

[0026] (1) Tumor PD-L1 expression detection products;

[0027] (2) Tumor detection products;

[0028] (3) In vitro pathological staining products for tumor tissues.

[0029] Specifically, the tumor includes benign tumor, malignant tumor or precancerous lesion tissue; and / or,

[0030] Specifically, the tumor includes one or more of breast cancer, colon cancer or melanoma; and / or,

[0031] Specifically, the product includes reagents and / or kits.

[0032] The fluorescent compound described in the present invention is obtained by coupling BMS-1166, a small molecule inhibitor targeting programmed death receptor 1 ligand-1 (PD-L1), with a fluorescent dye. Since BMS-1166 is a PD-L1 targeting ligand and can specifically bind to PD-L1, the fluorescent compound can be used for accurate imaging of tumors to detect PD-L1 expression; and since BMS-1166 has a high tumor specificity and its target molecule is lowly expressed in normal tissues, the fluorescent compound can specifically image tumor tissues and has a high signal-to-background ratio, and can be used to evaluate the expression of PD-L1 in tumors.

[0033] The fluorescent compound of the present invention preferably has the structure of a fluorescent dye, and then obtains the fluorescent compounds BMS-1166-5-FAM and BMS-1166-Cy5.5 of the preferred structure. The fluorescent compounds BMS-1166-5-FAM and BMS-1166-Cy5.5 of the present invention have excellent targeting as fluorescent probes at both the cellular level and the animal level, and can perform in vivo dynamic non-invasive evaluation of PD-L molecules expressed by tumors, solving the problem of tumor-specific imaging. The fluorescent compound can be used for precise imaging of tumors to detect PD-L1 expression, and can be used as a detection reagent for early detection of tumors such as breast cancer, colon cancer, and melanoma, and the probe complex has no toxic side effects, and has the advantages of safety, reliability, and a simple preparation process.

[0034] The present invention is based on the fluorescent compound as a tumor detection reagent. Experiments have shown that the tumor detection reagent of the present invention can achieve tumor imaging by targeting the immune target PD-L1 of breast cancer, colon cancer and melanoma foci, and can be used for early detection of tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:

[0036] Figure 1 The results of flow cytometric analysis of the binding of different tumor cell lines to the probe in Example 4; from left to right, they are the PBS group, the PD-L1 Block group, the BMS-1166 Block group, and the BMS-1166-5-FAM targeting group;

[0037] Figure 2 The results of observing the binding of the probe to melanoma B16F10-GFP cells using a laser confocal microscope in Example 5;

[0038] Figure 3 The results of in vivo fluorescence imaging of mice bearing breast 4T1 tumors before and after intravenous injection of the probe in Example 6;

[0039] Figure 4 The results of in vivo fluorescence imaging of mice bearing colon cancer CT26 tumors before and after intravenous injection of the probe in Example 6;

[0040] Figure 5 These are the results of in vivo fluorescence imaging of melanin B16F10-GFP tumor-bearing mice before and after intravenous injection of the probe in Example 6. DETAILED DESCRIPTION

[0041] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments and drawings. It should be understood by those skilled in the art that the content described below is illustrative rather than restrictive, and should not be used to limit the scope of protection of the present invention.

[0042] The technical solution of the present invention is not limited to the specific implementation modes listed below, but can be any combination of various implementation modes.

[0043] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.

[0044] It should be noted that the experimental methods used in the following examples are conventional methods unless otherwise specified. The instruments, materials, reagents, etc. used in the following examples are all available from conventional commercial channels unless otherwise specified.

[0045] In the following examples of the present invention, the sources of the tumor cell lines 4T1, CT26, and B16F10-GFP involved are as follows: 4T1 and CT26 were purchased from American Type Culture Collection (ATCC, USA); B16F10 was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences.

[0046] In the following embodiments of the present invention, the sources of experimental animals involved are as follows: BALB / c mice and C57BL / 6 mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0047] In the following embodiments of the present invention, the sources of the main instruments and consumables involved are as follows:

[0048] 12-well white bottom permeable cell culture plate (Costar product, product number No. 3513);

[0049] Fetal Bovine Serum (Gibco product, product number 10099141);

[0050] 100 mm culture dish (Corning product, product number 430167);

[0051] DMEM medium (Gibco product, product number 11965-084);

[0052] RPMI-1640 medium (from Gibco, Cat#A1049101);

[0053] DMSO (Sigma product, product number: No. D4540);

[0054] Flow cytometer (BD product, product model: Accuri C6, USA);

[0055] Fluorescence inverted microscope (Leica product, product model DMI3000B, Germany);

[0056] Optical imaging system with high detection sensitivity (PerkinElmer product, product model IVIS Spectrum, USA).

[0057] Example 1

[0058] This example is used to synthesize the probe BMS-1166-5-FAM, and the specific synthesis route is as follows:

[0059] .

[0060] Dissolve BMS-1166 (3.8 mg, 6.0 μmol) and 5-carboxyfluorescein (5-FAM, 2.2 mg, 6.0 μmol) in 1 mL N , N -dimethylformamide, then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 4.7 mg, 30.0 μmol) and 4-dimethylaminopyridine (DMAP, 0.7 mg, 0.6 μmol), and stir at room temperature for 24 hours. Collect the reaction product, add it to a silica gel column for purification, and elute it with a methanol-dichloromethane mixed solvent with a volume ratio of 10:1 as the eluent, collect the eluent part and remove the solvent under reduced pressure to obtain 1.8 mg of BMS-1166-5-FAM, with a calculated yield of 30.8%.

[0061] Example 2

[0062] This example is used to synthesize the probe BMS-1166-Cy5.5, and the specific synthesis route is as follows:

[0063] .

[0064] Take Cy5.5-COOH (3.7 mg, 6.0 μmol) and BMS-1166 (3.8 mg, 6.0 μmol) and dissolve them in 1 mL N , N -dimethylformamide, then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC, 4.7 mg, 30.0 μmol) and 4-dimethylaminopyridine (DMAP, 0.7 mg, 0.6 μmol), stir at room temperature for 24 hours, and remove under reduced pressure. N , N The reaction product was collected, added to a silica gel column for purification, and eluted with a methanol-dichloromethane mixed solvent with a volume ratio of 10:1 as an eluent. The eluent was collected and the solvent was removed under reduced pressure to obtain 2.1 mg of BMS-1166-Cy5.5, with a calculated yield of 29.6%.

[0065] Example 3 Cell culture

[0066] The complete culture medium required for each cell was prepared, wherein the complete culture medium consisted of 80-90% DMEM or 1640 and 10-20% fetal bovine serum, and a double antibody storage solution (penicillin + streptomycin) was added at a volume fraction of 1% of the culture medium, and the final concentrations of penicillin and streptomycin were 100 U / mL and 100 μg / mL, respectively.

[0067] Before the experiment begins, confirm the name of the cell line, culture medium, subculture time, generation number and other information marked on the 100 mm culture dish to ensure the experiment is correct.

[0068] Use a sterile pipette to absorb the cell culture medium, rinse the cell surface with 5 mL of sterile PBS solution, and then use a sterile pipette to aspirate the PBS waste liquid. Add 1 mL of 0.25% (w / v) trypsin solution containing 0.04% (w / v) EDTA to the culture medium to digest the cells, mix gently so that the solution covers the cell surface, observe under a microscope, and add 10 mL of complete culture medium and pipette when the cells are completely detached from the bottom of the culture dish and the cell connection is loose. After separating the cells into single cells, transfer the cell suspension to a 15 mL sterile centrifuge tube and centrifuge at 1000 rpm for 5 min. Use a sterile pipette to aspirate the supernatant culture medium, add 5 mL of fresh complete culture medium to resuspend the cell pellet, and gently pipette to mix.

[0069] The cell suspension was counted using a cell counting plate, the concentration of the cell suspension was adjusted and inoculated into a 12-well culture plate for a plating experiment. The cell density was 2×10 5 cells / well and culture overnight to allow the cells to fully adhere.

[0070] Example 4

[0071] In this example, flow cytometry was used to detect the in vitro targeting and specificity of the probe to be tested.

[0072] 1 mL of 15 μg / mL BMS-1166-5-FAM was added to each well of a 12-well culture plate. An equal volume of PBS was added to the control group, 150 μg / mL PD-L1 antibody and 15 μg / mL BMS-1166-5-FAM were added to the PD-L1 Block group, and 150 μg / mL BMS-1166 and 15 μg / mL BMS-1166-5-FAM were added to the BMS-1166 Block group.

[0073] The cells in the above culture plate were incubated for 0.5 h and then washed three times with PBS.

[0074] Take 0.2 mL of 0.25% (w / v) trypsin solution containing 0.04% (w / v) EDTA to digest the cells, mix gently so that the solution covers the surface of the cells, observe under a microscope, and add 2 mL of complete culture medium and pipette when the cells are completely detached from the bottom of the 12-well culture plate and the cell connections are loose.

[0075] The cell suspensions were placed in 1.5 mL centrifuge tubes, centrifuged at 1000 rpm for 5 min, washed 3 times with sterile PBS, and tested by flow cytometry. The results are shown in the attached Figure 1 .

[0076] As attached Figure 1 The results of flow cytometer analysis of probe uptake by different cell lines are shown. It can be seen that compared with the control group, breast cancer cells 4T1 and colon cancer cells CT26 have good uptake of the probe BMS-1166-5-FAM to be tested; under the same conditions, the uptake of 4T1 and CT26 cells in the PD-L1 Block group and BMS-1166 Block group with blockers added is significantly lower than that of the probe BMS-1166-5-FAM group without blockers. These results show that the probe in this example has good tumor targeting and specificity.

[0077] Example 5

[0078] In this example, a laser confocal microscope was used to observe the uptake of the probe to be detected by melanoma B16F10-GFP cells.

[0079] Use a sterile pipette to remove the culture medium from the confocal dish. Add 1 mL of 15 μg / mL BMS-1166-5-FAM to each dish. For the PD-L1 Block group, add 150 μg / mL PD-L1 antibody and 15 μg / mL BMS-1166-5-FAM at the same time. For the BMS-1166 Block group, add 150 μg / mL BMS-1166 and 15 μg / mL BMS-1166-5-FAM at the same time. Place the dish in a 37°C incubator and continue culturing for 4 hours.

[0080] Use a sterile pipette to suck out the waste medium, add 2 mL of sterile PBS / well to wash the cell surface three times, then use a sterile pipette to suck out the waste PBS, and fix the cells with 4% paraformaldehyde for 30 min.

[0081] Use a sterile pipette to suck out 4% paraformaldehyde, wash three times with PBS, then add 0.5% Triton solution, suck out the solution with a pipette after 30 minutes, and wash three times with PBS.

[0082] Continue to add 5% BSA to block for 30 min, wash with PBS three times, then add DAPI solution with a concentration of 100 ng / ml, aspirate the solution with a pipette after 8 min, and wash with PBS three times.

[0083] Continue to add anti-fluorescence quenching PVP sealing liquid, and observe the cells under a laser confocal microscope. The results are shown in the attached Figure 2 .

[0084] As attached Figure 2 The results of laser confocal microscopy observation of B16F10-GFP probe uptake are shown. It can be seen that the probe BMS-1166-5-FAM showed strong fluorescence signals in B16F10-GFP cells, while the PD-L1 Block group and BMS-1166 Block group with blockers did not show fluorescence signals in B16F10-GFP cells. These results show that the probe BMS-1166-5-FAM can be specifically taken up by melanoma B16F10-GFP cells.

[0085] Example 6

[0086] This example uses animal experiments to detect the in vivo targeting and accuracy of the drug to be tested.

[0087] (1) Establishment of tumor-bearing mouse model

[0088] 4T1, CT26 and B16F10-GFP tumor cells were centrifuged at 1000 rpm for 5 min, and then washed with sterile PBS for 3 times. The cells were appropriately diluted and counted with a hemocytometer to obtain a concentration of 1×10 7 Each mouse was subcutaneously inoculated with 50 μL of tumor cell suspension of cells / ml. 4T1 and CT26 were inoculated subcutaneously in the right hind limb of the back of BALB / c mice, and B16F10 was inoculated subcutaneously in the right hind limb of the back of C57BL / 6 mice.

[0089] After the inoculation, the inoculation site was observed for infection and the tumor was observed to see if it naturally subsided after growth. 3 Imaging experiments were started at .

[0090] (2) Targeted verification

[0091] 5-10 days after tumor inoculation, 0.1 mL of the above-mentioned BMS-1166-Cy5.5 solution at 3 mg / mL was intravenously injected. The PD-L1 Block blocking group was injected with 0.1 mL of 150 mg / mL PD-L1 antibody and 0.1 mL of 3 mg / mL BMS-1166-Cy5.5 at the same time. The BMS-1166 Block blocking group was injected with 0.1 mL of 150 mg / mL BMS-1166 and 0.1 mL of 3 mg / mL BMS-1166-Cy5.5 at the same time. Subsequently, a high-sensitivity optical imaging system analyzer was used to monitor the fluorescence signal in the mice before and 12 hours after the probe injection. 24 hours after the probe injection, the main organs and tumor tissues of the mice were removed for imaging. The results are shown in the attached figure. Figure 3-5 .

[0092] As attached Figure 3 The results of in vivo fluorescence imaging of mice bearing breast cancer 4T1 tumors before and 12 hours after intravenous injection of the probe are shown. Figure 3 As shown in (A), 12 hours after the injection of the probe BMS-1166-Cy5.5, the probe showed good enrichment in the tumor tissue. The signal-to-noise ratio of the tumor and the surrounding normal tissue in the BMS-1166-Cy5.5 group exceeded 7, while at the same time point, the signal-to-noise ratio of the PD-L1 Block and BMS-1166 Block blocking groups was less than 6; 24 hours after the probe injection, further tissue and organ in vitro imaging results showed that the tumor fluorescence intensity of the probe BMS-1166-Cy5.5 injection group was significantly higher than that of the PD-L1 Block and BMS-1166 Block blocking groups (see Appendix Figure 3 These results indicate that the probe BMS-1166-Cy5.5 has good targeting to 4T1 tumors and can be used for imaging of 4T1 tumors.

[0093] As attached Figure 4 The results of in vivo fluorescence imaging of mice bearing colon cancer CT26 tumors before and 12 hours after intravenous injection of the probe are shown in the attached figure. Figure 4 As shown in (A), 12 hours after the injection of the probe BMS-1166-Cy5.5, the probe showed good enrichment in the tumor tissue, and the signal-to-noise ratio of the tumor and the surrounding normal tissue exceeded 7, while at the same time point, the signal-to-noise ratio of the PD-L1 Block and BMS-1166 Block blocking groups was less than 5; 24 hours after the probe injection, further tissue and organ in vitro imaging results showed that the tumor fluorescence intensity of the probe BMS-1166-Cy5.5 injection group was significantly higher than that of the PD-L1 Block and BMS-1166 Block blocking groups (see Appendix Figure 4 These results indicate that the probe BMS-1166-Cy5.5 has good targeting ability to CT26 tumors.

[0094] As attached Figure 5 The results of in vivo fluorescence imaging of mice bearing melanin B16F10-GFP tumors before and 12 hours after intravenous injection of the probe are shown in the attached figure. Figure 5As shown in (A), when the probe BMS-1166-Cy5.5 was injected for 12 hours, the probe showed good enrichment in the tumor tissue, and the signal-to-noise ratio of the tumor and the surrounding normal tissue exceeded 12; at the same time point, the signal-to-noise ratio of the PD-L1 Block and BMS-1166 Block blocking groups was less than 10, significantly lower than that of the probe BMS-1166-Cy5.5; further tissue and organ in vitro imaging results 24 hours after the probe injection showed that the tumor fluorescence intensity of the probe BMS-1166-Cy5.5 injection group was significantly higher than that of the PD-L1 Block and BMS-1166 Block blocking groups (see Appendix Figure 5 These results indicate that the probe BMS-1166-Cy5.5 has good targeting ability to B16F10-GFP tumors.

[0095] In summary, the fluorescent compounds BMS-1166-5-FAM and BMS-1166-Cy5.5 of the present invention have excellent targeting properties as fluorescent probes at both the cellular level and the animal level, and can perform dynamic and non-invasive in vivo evaluation of PD-L molecules expressed by tumors, thus solving the problem of tumor-specific imaging and can be used for tumor imaging detection.

[0096] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A fluorescent compound, characterized in that: The fluorescent compound is selected from the compound BMS-1166-5-FAM having a structure shown in the following formula (a) or the compound BMS-1166-Cy5.5 having a structure shown in the following formula (b): 。 2. A method for preparing the fluorescent compound as claimed in claim 1, characterized in that: The steps include: (1) In an organic solvent system, compound BMS-1166 and a fluorescent raw material of a selected structure are taken, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 4-dimethylaminopyridine are added to react; The fluorescent material is selected from 5-carboxyfluorescein or Cy5.5-COOH; (2) Collect the reactants and purify them on a silica gel column to obtain the product.

3. The method for preparing the fluorescent compound according to claim 2, characterized in that: In the step (1), The molar ratio of the compound BMS-1166, the fluorescent raw material, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide and 4-dimethylaminopyridine is 1:1:5:0.

1.

4. The method for preparing the fluorescent compound according to claim 2 or 3, characterized in that: In the step (2), the silica gel column purification step includes the step of eluting with a mixed solvent of methanol and dichloromethane, and the step of removing the solvent under reduced pressure.

5. A PD-L1 targeting probe, characterized in that: The invention comprises the fluorescent compound as claimed in claim 1.

6. A tumor detection preparation, characterized in that: It includes the fluorescent compound according to claim 1 or the PD-L1 targeting probe according to claim 5.

7. Use of the fluorescent compound according to claim 1 for preparing a product having at least one of the following effects (1) to (3): (1) Tumor PD-L1 expression detection products; (2) Tumor detection products; (3) In vitro pathological staining products for tumor tissues.

8. The use according to claim 7, characterized in that The tumor includes benign tumor, malignant tumor or precancerous lesion tissue.

9. The use according to claim 8, characterized in that The tumor includes one or more of breast cancer, colon cancer or melanoma.

10. The use according to claim 7, characterized in that The products include reagents and / or kits.